Pediatric Hematopathology in the Era of Advanced Molecular Diagnostics: What We Know and How We Can Apply the Updated Classifications
暂无分享,去创建一个
[1] E. Solary,et al. Juvenile myelomonocytic leukemia; moving forward , 2023, Leukemia.
[2] W. Stock,et al. Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients , 2022, Haematologica.
[3] M. Loh,et al. Clinical characteristics and outcomes of B-cell precursor ALL with MEF2D rearrangements: a retrospective study by the Ponte di Legno Childhood ALL Working Group , 2022, Leukemia.
[4] M. Rudelius,et al. Classification of rare pediatric myeloid neoplasia—Quo vadis? , 2022, Leukemia.
[5] S. Spellman,et al. Germline predisposition variants occur in myelodysplastic syndrome patients of all ages. , 2022, Blood.
[6] Y. Natkunam,et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms , 2022, Leukemia.
[7] A. Rosenwald,et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms , 2022, Leukemia.
[8] L. Staudt,et al. The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee. , 2022, Blood.
[9] M. Seidel,et al. P816: TRANSIENT MONOSOMY 7 IN SAMD9/9L SYNDROMES: IS IT SAFE TO WATCH AND WAIT? , 2022, HemaSphere.
[10] M. Konopleva,et al. High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse , 2022, Blood advances.
[11] A. Shimamura,et al. Lessons From Pediatric MDS: Approaches to Germline Predisposition to Hematologic Malignancies , 2022, Frontiers in Oncology.
[12] A. Stemmer-Rachamimov,et al. N‐terminus DUX4‐immunohistochemistry is a reliable methodology for the diagnosis of DUX4‐fused B‐lymphoblastic leukemia/lymphoma (N‐terminus DUX4 IHC for DUX4‐fused B‐ALL) , 2022, Genes, chromosomes & cancer.
[13] Michael C. Rusch,et al. Integrated Genomic Analysis Identifies UBTF Tandem Duplications as a Recurrent Lesion in Pediatric Acute Myeloid Leukemia , 2022, Blood cancer discovery.
[14] J. Tchinda,et al. Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9/SAMD9L syndromes , 2021, Nature Medicine.
[15] A. Yeoh,et al. Distinct clinical characteristics of DUX4- and PAX5-altered childhood B-lymphoblastic leukemia , 2021, Blood advances.
[16] M. Loh,et al. Juvenile myelomonocytic leukemia in the molecular era: a clinician’s guide to diagnosis, risk stratification, and treatment , 2021, Blood advances.
[17] Anna L. Brown,et al. Childhood Acute Myeloid Leukemia shows a high level of germline predisposition. , 2021, Blood.
[18] R. Stam,et al. Favorable outcome of NUTM1-rearranged infant and pediatric B cell precursor acute lymphoblastic leukemia in a collaborative international study , 2021, Leukemia.
[19] W. Carroll,et al. Minimal Residual Disease in Acute Lymphoblastic Leukemia: Current Practice and Future Directions , 2021, Cancers.
[20] M. Loh,et al. Clinical characteristics and outcomes of B-ALL with ZNF384 rearrangements: a retrospective analysis by the Ponte di Legno Childhood ALL Working Group , 2021, Leukemia.
[21] H. Dombret,et al. Minimal residual disease monitoring in acute myeloid leukemia with non-A/B/D NPM1 mutations by digital polymerase chain reaction: feasibility and clinical use , 2020, Haematologica.
[22] S. Vercauteren,et al. Clinical and laboratory features associated with myeloperoxidase expression in pediatric B‐lymphoblastic leukemia , 2020, Cytometry. Part B, Clinical cytometry.
[23] D. Berry,et al. Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis. , 2020, JAMA oncology.
[24] M. Wlodarski,et al. Germline predisposition in myeloid neoplasms: Unique genetic and clinical features of GATA2 deficiency and SAMD9/SAMD9L syndromes , 2020, Best Practice & Research Clinical Haematology.
[25] L. Saal,et al. Subclonal patterns in follow-up of acute myeloid leukemia combining whole exome sequencing and ultrasensitive IBSAFE digital droplet analysis , 2020, Leukemia & lymphoma.
[26] K. Stamatopoulos,et al. Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study , 2019, Leukemia.
[27] C. Dinardo,et al. Hereditary myeloid malignancies. , 2019, Best practice & research. Clinical haematology.
[28] Daniela Cilloni,et al. Digital PCR in Myeloid Malignancies: Ready to Replace Quantitative PCR? , 2019, International journal of molecular sciences.
[29] C. Bloomfield,et al. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. , 2019, Blood.
[30] C. Niemeyer,et al. Juvenile myelomonocytic leukemia: who's the driver at the wheel? , 2019, Blood.
[31] N. Popitsch,et al. CD371 cell surface expression: a unique feature of DUX4-rearranged acute lymphoblastic leukemia , 2019, Haematologica.
[32] Ashley D. Hill,et al. PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia , 2019, Nature Genetics.
[33] M. Fleming,et al. Bone Marrow Morphology Associated With Germline RUNX1 Mutations in Patients With Familial Platelet Disorder With Associated Myeloid Malignancy , 2019, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.
[34] W. Klapper,et al. IG-MYC + neoplasms with precursor B-cell phenotype are molecularly distinct from Burkitt lymphomas. , 2018, Blood.
[35] M. Loh,et al. Germline SAMD9 and SAMD9L mutations are associated with extensive genetic evolution and diverse hematologic outcomes. , 2018, JCI insight.
[36] F. Locatelli,et al. How I treat myelodysplastic syndromes of childhood. , 2018, Blood.
[37] Torsten Haferlach,et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. , 2018, Blood.
[38] Michael C. Heinold,et al. The landscape of genomic alterations across childhood cancers , 2018, Nature.
[39] M. Loh,et al. Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia , 2017, Nature Communications.
[40] A. Savoia,et al. Inherited thrombocytopenia caused by ANKRD26 mutations misdiagnosed and treated as myelodysplastic syndrome: report on two cases , 2017, Journal of thrombosis and haemostasis : JTH.
[41] T. Fioretos,et al. New oncogenic subtypes in pediatric B-cell precursor acute lymphoblastic leukemia. , 2017, Blood.
[42] Melanie Boerries,et al. RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia , 2017, Nature Communications.
[43] J. Liesveld,et al. Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in older adults: Current treatment and novel therapies. , 2017, Best practice & research. Clinical haematology.
[44] J. Stuchly,et al. ETV6/RUNX1‐like acute lymphoblastic leukemia: A novel B‐cell precursor leukemia subtype associated with the CD27/CD44 immunophenotype , 2017, Genes, chromosomes & cancer.
[45] A. Shimamura,et al. Genetic predisposition to hematologic malignancies: management and surveillance. , 2017, Blood.
[46] Richard A. Moore,et al. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions , 2017, bioRxiv.
[47] A. Shimamura,et al. Germline Genetic Predisposition to Hematologic Malignancy. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] W. Ouwehand,et al. Germline variants in ETV6 underlie reduced platelet formation, platelet dysfunction and increased levels of circulating CD34+ progenitors , 2017, Haematologica.
[49] Heather L. Mulder,et al. Pediatric non–Down syndrome acute megakaryoblastic leukemia is characterized by distinct genomic subsets with varying outcomes , 2017, Nature Genetics.
[50] K. Okamura,et al. ZNF384-related fusion genes define a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with a characteristic immunotype , 2017, Haematologica.
[51] J. Klco,et al. The genomic landscape of pediatric myelodysplastic syndromes , 2016, Nature Communications.
[52] H. Hasle. Myelodysplastic and myeloproliferative disorders of childhood. , 2016, Hematology. American Society of Hematology. Education Program.
[53] T. Walsh,et al. Genetic features of myelodysplastic syndrome and aplastic anemia in pediatric and young adult patients , 2016, Haematologica.
[54] M. Loh,et al. Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group Study AALL0232. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[55] Mario Cazzola,et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.
[56] Andrew P. Voigt,et al. A recurrent immunophenotype at diagnosis independently identifies high-risk pediatric acute myeloid leukemia: a report from Children’s Oncology Group , 2016, Leukemia.
[57] Shinichi Morishita,et al. Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults , 2016, Nature Genetics.
[58] M. Wlodarski,et al. Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents. , 2016, Blood.
[59] S. Raimondi,et al. Heterogeneous cytogenetic subgroups and outcomes in childhood acute megakaryoblastic leukemia: a retrospective international study. , 2015, Blood.
[60] J. Downing,et al. Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[61] D. Reinhardt,et al. Improved outcome of pediatric patients with acute megakaryoblastic leukemia in the AML-BFM 04 trial , 2015, Annals of Hematology.
[62] C. Niemeyer,et al. How I treat juvenile myelomonocytic leukemia. , 2015, Blood.
[63] P. Campbell,et al. Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. , 2014, Blood.
[64] A. Baruchel,et al. Juvenile myelomonocytic leukaemia and Noonan syndrome , 2014, Journal of Medical Genetics.
[65] Robert K Hills,et al. Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[66] V. V. D. van der Velden,et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[67] S. Miyano,et al. The landscape of somatic mutations in Down syndrome–related myeloid disorders , 2013, Nature Genetics.
[68] J. Rubnitz. How I treat pediatric acute myeloid leukemia. , 2012, Blood.
[69] Xiaomin Lu,et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[70] Franco Locatelli,et al. Spliceosomal gene aberrations are rare, coexist with oncogenic mutations, and are unlikely to exert a driver effect in childhood MDS and JMML. , 2012, Blood.
[71] S. Devesa,et al. Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. , 2012, Blood.
[72] C. Plass,et al. Aberrant DNA methylation characterizes juvenile myelomonocytic leukemia with poor outcome. , 2011, Blood.
[73] F. Berrino,et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. , 2010, Blood.
[74] M. Loh,et al. Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia , 2010, Nature Genetics.
[75] A. Baruchel,et al. Germline mutations of the CBL gene define a new genetic syndrome with predisposition to juvenile myelomonocytic leukaemia , 2010, Journal of Medical Genetics.
[76] A. Yoshimi,et al. Correlation of Clinical Features With the Mutational Status of GM-CSF Signaling Pathway-Related Genes in Juvenile Myelomonocytic Leukemia , 2009, Pediatric Research.
[77] D. Reinhardt,et al. AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity , 2005, Leukemia.
[78] H. Kantarjian,et al. Long‐term follow‐up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper‐CVAD), a dose‐intensive regimen, in adult acute lymphocytic leukemia , 2004, Cancer.
[79] H. Cavé,et al. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program , 2003, Leukemia.
[80] M. Vignetti,et al. Acute megakaryoblastic leukemia: experience of GIMEMA trials , 2002, Leukemia.
[81] F. Behm,et al. Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution's experience. , 2001, Blood.
[82] J. Harbott,et al. Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS) , 1997, Blood.
[83] M. Heuser,et al. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party , 2021 .
[84] S. Holland,et al. GATA2 deficiency-associated bone marrow disorder differs from idiopathic aplastic anemia. , 2015, Blood.
[85] J. Wagner,et al. Diagnosis of myelodysplastic syndrome among a cohort of 119 patients with fanconi anemia: morphologic and cytogenetic characteristics. , 2010, American journal of clinical pathology.
[86] B. Lange,et al. Myelodysplastic and Myeloproliferative Disorders of Childhood : A Study of 167 Patients , 1998 .